Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05361707 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
A Phase 3 study of Autism Spectrum Disorder and Sleep Disturbance, sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT05361707: Recruiting Phase 3 study of Autism Spectrum Disorder and Sleep Disturbance, sponsored by Vanda Pharmaceuticals.
NCT05361707 is a Phase 3 study of Autism Spectrum Disorder and Sleep Disturbance that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 100 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (26% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05361707, a Phase 3 study of Autism Spectrum Disorder and Sleep Disturbance, is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.
Conditions Studied
Interventions
- DRUG Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Study Locations (5)
California
- Vanda Investigational Site - San Jose
- Vanda Investigational Site - San Leandro
- Vanda Investigational Site - Santa Monica
Colorado
- Vanda Investigational Site - Boulder
New York
- Vanda Investigational Site - Staten Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2025-07 |
| Phase | Phase 3 |
What NCT05361707 shows while recruiting
NCT05361707 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (26% lower).
The record links to 4 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension is the first listed.
NCT05361707 lists 5 locations in 3 states (California, Colorado, New York).
Frequently Asked Questions
What is clinical trial NCT05361707 about?
NCT05361707 is a clinical study titled "Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances". This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.
What is the current status of trial NCT05361707?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2021-07-28. Estimated completion is 2025-07.
What conditions does trial NCT05361707 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Sleep Disturbance, Sleep Disorder, Neurological Disorder.
What interventions are being tested in trial NCT05361707?
The interventions under investigation include: Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension (DRUG).
Who is sponsoring clinical trial NCT05361707?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05361707 being conducted?
This trial has 5 study locations across California, Colorado, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05361707's enrollment target sits among peer trials
100 71st of 224 higher than 147 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RECRUITING · Phase 3
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI